# Alpha Tau Medical's Early Trial Shows 100% Response in Six Evaluated Patients

> Alpha Tau Medical reported all six assessed patients responded in its early Alpha DaRT trial, with all eight treated patients alive as of November 11.

- Published: 2026-11-15T19:01:34+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-15/alpha-tau-medical-trial-response
- Source: [TradingView](https://www.tradingview.com/news/tradingview:58af23bb53359:0-alpha-tau-medical-ltd-drts-reports-responses-in-all-six-evaluable-patients/)

## Key takeaways

- All eight patients treated in Alpha Tau Medical's early-stage trial were alive as of November 11, with median overall survival not reached.
- Six of six assessed patients had an objective response, including five complete responses and one partial response.
- Median follow-up was 6.9 months, and the trial is designed to enroll up to 20 patients.

Alpha Tau Medical reported that all six evaluated patients in an early-stage trial had an objective response, with five complete responses and one partial response, as of November 11. The Israel-based oncology company said all eight treated patients remained alive and median overall survival was not reached, [TradingView](https://www.tradingview.com/news/tradingview:58af23bb53359:0-alpha-tau-medical-ltd-drts-reports-responses-in-all-six-evaluable-patients/) reported on November 15.

## Inside the Alpha DaRT Interim Results

[Alpha Tau Medical](https://akta.pro/company-profiles/0000jco/alpha-tau-medical) develops Alpha DaRT, an intratumoral radium-224 radiation therapy for solid tumors. The interim update covers a single-arm trial designed to enroll up to 20 patients, with eight treated and six assessed so far.

Median follow-up among the six assessed patients was 6.9 months. Responses in three recently assessed patients remain subject to confirmation, the company said. Sources were deployed in all eight patients, and no unanticipated serious adverse events were reported; one previously reported grade 3 serious adverse event occurred.

The company said further enrollment and follow-up are needed to establish durability and support any regulatory submission.

## Alpha Tau's Cash and Financing Position

According to akta.pro [company records](https://akta.pro/company-data), Alpha Tau held $80.2 million in cash, cash equivalents, short-term deposits and restricted deposits as of March 31, 2026. The same records show a $22.9 million net loss in the first quarter of 2026, compared with $8.7 million a year earlier, and total funding of $208.6 million.

## Earlier Alpha DaRT Trial Milestones

In July 2026, Alpha Tau reported positive results from a single-center trial combining Alpha DaRT with pembrolizumab, with a 100% objective response rate in elderly patients with advanced head and neck squamous cell carcinoma; the trial stopped early for success, Yahoo reported. In September 2026, the company completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, expanding from 12 to 48 participants across 10 sites, according to Simply Wall St.

## ReSTART Data Expected Around Year-End

Alpha Tau's first U.S. pivotal trial, ReSTART, completed enrollment at 88 patients, with top-line data expected around year-end 2026 or early 2027, AInvest reported.

## Companies in this story

- [Alpha Tau Medical company profile](https://akta.pro/company-profiles/0000jco/alpha-tau-medical) · website: https://www.alphatau.com

---
News for Agent · https://newsforagent.com/llms.txt